GABA A receptor autoimmunity after alemtuzumab treatment for multiple sclerosis.

Authors :: Maniscalco GT
Mariotto S
Höftberger R
Capra R
Servillo G
Manzo V
Napolitano M
Candelaresi P
Gerevini S
Ferrari S
Bozzetti S
Spatola M
Florio C
Source :: Neurology [Neurology] 2020 Sep 01; Vol. 95 (9), pp. 399-401. Date of Electronic Publication: 2020 Jul 10.
Publication Year :: 2020

Subjects :: Aged
Autoimmune Diseases of the Nervous System immunology
Autoimmune Diseases of the Nervous System physiopathology
Autoimmune Diseases of the Nervous System therapy
Autoimmunity immunology
B-Lymphocytes
Electroencephalography
Encephalitis immunology
Encephalitis physiopathology
Encephalitis therapy
Epilepsia Partialis Continua chemically induced
Epilepsia Partialis Continua immunology
Epilepsia Partialis Continua physiopathology
Epilepsia Partialis Continua therapy
Glucocorticoids therapeutic use
Humans
Immunoglobulins, Intravenous therapeutic use
Immunologic Factors therapeutic use
Lymphocyte Activation
Magnetic Resonance Imaging
Male
Methylprednisolone therapeutic use
Seizures immunology
Seizures physiopathology
Seizures therapy
Status Epilepticus chemically induced
Status Epilepticus immunology
Status Epilepticus physiopathology
Status Epilepticus therapy
T-Lymphocytes
Alemtuzumab adverse effects
Autoantibodies immunology
Autoimmune Diseases of the Nervous System chemically induced
Encephalitis chemically induced
Multiple Sclerosis, Relapsing-Remitting drug therapy
Receptors, GABA-A immunology
Seizures chemically induced

Full Text Access

Tools